BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Biotech catalysts in 2024-11

212 industry Phase 2/3 trial readout(s) and 32 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.

← 2024-10 | 2024-12 →

FDA decision events

DateEventStatusCompanyDrugSource
2024-11-01FDA approvalapprovedJOURNEY DERMEMROSIApproved 2024-11-01: EMROSI (NDA219015 ORIG1)
2024-11-04Complete response letterapproved sinceAzurity Pharmaceuticals, Inc.sitagliptin oral solutionCRL 2024-11-04: Azurity Pharmaceuticals, Inc. NDA 219122 (sitagliptin oral solution)
2024-11-07FDA AdComheldAdCom 2024-11-07: General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee
2024-11-07FDA approvalapprovedAZURITYDANZITENApproved 2024-11-07: DANZITEN (NDA219293 ORIG1)
2024-11-09FDA approvalapprovedDJB GAS SERVICES, INCCarbon Dioxide USPApproved 2024-11-09: Carbon Dioxide, USP (NDA220050 ORIG1)
2024-11-13FDA approvalapprovedELI LILLY AND CO LLYVERZENIOApproved 2024-11-13: VERZENIO (NDA208716 SUPPL17)
2024-11-14Complete response lettercomplete responseLupin Limited (Biotech Division)LUBT004CRL 2024-11-14: Lupin Limited (Biotech Division) BLA 761212 (LUBT004)
2024-11-15Complete response letterapproved sinceAstellas Pharma US, IncIZERVAY (avacincaptad pegol intravitreal solution)CRL 2024-11-15: Astellas Pharma US, Inc NDA 217225/S-001 (IZERVAY (avacincaptad pegol intravitreal solution))
2024-11-15FDA approvalapprovedSYNDAX SNDXREVUFORJApproved 2024-11-15: REVUFORJ (NDA218944 ORIG1)
2024-11-19FDA AdComheldAdCom 2024-11-19: Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Psychopharmacologic Drugs Advisory Committee
2024-11-19FDA approvalapprovedUCB INCBIMZELXApproved 2024-11-19: BIMZELX (BLA761151 SUPPL10)
2024-11-19FDA approvalapprovedCAPLIN ONE LABSFLUDARABINE PHOSPHATEApproved 2024-11-19: FLUDARABINE PHOSPHATE (NDA022137 SUPPL15)
2024-11-20FDA approvalapprovedJAZZ PHARMS JAZZZIIHERAApproved 2024-11-20: ZIIHERA (BLA761416 ORIG1)
2024-11-21FDA AdComheldAstraZeneca AB AZNAdCom 2024-11-21: Cellular, Tissue, and Gene Therapies Advisory Committee
2024-11-21FDA approvalapprovedMAIA PHARMS INCDAPTOMYCINApproved 2024-11-21: DAPTOMYCIN (NDA217630 ORIG1)
2024-11-22FDA approvalapprovedGENENTECH INCPHESGOApproved 2024-11-22: PHESGO (BLA761170 SUPPL7)
2024-11-22FDA approvalapprovedGENENTECH INCLUNSUMIO LUNSUMIO VELOApproved 2024-11-22: LUNSUMIO; LUNSUMIO VELO (BLA761263 SUPPL5)
2024-11-22FDA approvalapprovedJANSSEN BIOTECHTECVAYLIApproved 2024-11-22: TECVAYLI (BLA761291 SUPPL9)
2024-11-22FDA approvalapprovedAOP HLTH USRAPIBLYKApproved 2024-11-22: RAPIBLYK (NDA217202 ORIG1)
2024-11-22FDA approvalapprovedSHORLA ONCOLOGYIMKELDIApproved 2024-11-22: IMKELDI (NDA219097 ORIG1)
2024-11-22FDA approvalapprovedMYLAN IRELAND LTDPRETOMANIDApproved 2024-11-22: PRETOMANID (NDA212862 SUPPL8)
2024-11-22FDA approvalapprovedIMMUNOMEDICS INCTRODELVYApproved 2024-11-22: TRODELVY (BLA761115 SUPPL58)
2024-11-22FDA approvalapprovedBRIDGEBIO PHARMA BBIOATTRUBYApproved 2024-11-22: ATTRUBY (NDA216540 ORIG1)
2024-11-25FDA approvalapprovedGILEAD SCIENCES INC GILDSUNLENCAApproved 2024-11-25: SUNLENCA (NDA215973 SUPPL6)
2024-11-25FDA approvalapprovedGILEAD SCIENCES INC GILDSUNLENCAApproved 2024-11-25: SUNLENCA (NDA215974 SUPPL8)
2024-11-26FDA approvalapprovedAPOTEXACETADOTEApproved 2024-11-26: ACETADOTE (NDA021539 SUPPL19)
2024-11-26FDA approvalapprovedKAMATRALDESYApproved 2024-11-26: RALDESY (NDA218637 ORIG1)
2024-11-27Complete response lettercomplete responseApplied Therapeutics, Inc. AMATgovorestatCRL 2024-11-27: Applied Therapeutics, Inc. NDA 219195 (govorestat)
2024-11-27FDA approvalapprovedBRACCOIOMERVUApproved 2024-11-27: IOMERVU (NDA216016 ORIG1)
2024-11-27FDA approvalapprovedBRACCOIOMERVUApproved 2024-11-27: IOMERVU (NDA216017 ORIG1)
2024-11-27FDA approvalapprovedNOVO NVOWEGOVY WEGOVY FLEXTOUCH WEGOVY HDApproved 2024-11-27: WEGOVY; WEGOVY FLEXTOUCH; WEGOVY HD (NDA215256 SUPPL15)
2024-11-29FDA approvalapprovedBIOCON BIOLOGICS INCYESINTEKApproved 2024-11-29: YESINTEK (BLA761406 ORIG1)

Trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2024-11 est.P1/P2Cortice Biosciences, Inc.NCT01933815 Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for GlioblastomaGlioblastoma Multiformesuspended92
2024-11P2Candel Therapeutics, Inc. CADLNCT02768363 Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)Prostate Canceractive not recruiting187
2024-11 est.P3SurgimabNCT03659448 Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal CancerColorectal Neoplasmsrecruiting300
2024-11 est.P1/P2Kartos Therapeutics, Inc.NCT03787602 Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell CarcinomaMerkel Cell Carcinomaunknown115
2024-11 est.P2Silk Road Therapies, Inc.NCT04186559 Topical Pentoxifylline Gel on Behcet's Disease Genital UlcersBehcet Syndrome; Behcet Diseaseunknown60
2024-11 est.P1/P2Telios Pharma, Inc.NCT04669067 TL-895 and KRT-232 Study in Acute Myeloid LeukemiaAcute Myeloid Leukemiaunknown18
2024-11 est.P3MaaT PharmaNCT04769895 MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD PatientsAcute Graft Versus Host Disease in Intestine; Steroid Refractory GVHDunknown66
2024-11 est.P1/P2Direct Biologics, LLCNCT05116761 ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 SyndromeCovid19; Postviral Syndrome; Dyspneawithdrawn
2024-11 est.P1/P2Myeloid TherapeuticsNCT05138458 A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCLLymphoma, T-Cell, Peripheral; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Adoptive Cellular Immususpended40
2024-11 est.P2Bazell Pharma AGNCT05214599 Pharmacokinetics, Efficacy, Tolerability and Safety of Different Budesonide Oral Gel Doses in Adults' Subjects of Both Genders With Eosinophilic Esophagitis (EoEosinophilic Esophagitiswithdrawn
2024-11 est.P2Vitti Labs, LLCNCT05387239 Safety and Effectiveness of VL-PX10 + VL-P22 Treatment on Pulmonary Fibrosis Secondary to Covid-19Pulmonary Fibrosis; COVID-19 Respiratory Infectionsuspended20
2024-11 est.P2Onconic Therapeutics Inc.NCT05475184 A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP InhibitorOvarian Cancerunknown58
2024-11 est.P2Kira Pharmacenticals (US), LLC.NCT05476887 To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104Paroxysmal Nocturnal Hemoglobinuriaunknown35
2024-11 est.P1/P2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05625919 A Study of Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa)Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa)unknown54
2024-11 est.P3EMSNCT05684380 Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)Allergic Rhinitisunknown514
2024-11 est.P2GoloNCT05844644 The Effects of the GOLO for Life® Plan With Release Supplement on Glycemic Control and Weight in Overweight and Obese Adults With Prediabetes or Type 2 DiabetesType 2 Diabetes; Obese; Overweight; Prediabetesunknown100
2024-11 est.P2Amydis Inc.NCT06223048 A Study of AMDX-2011P in Participants With Primary Open Angle GlaucomaPrimary Open Angle Glaucomaunknown50
2024-11 est.P2DermBiont, Inc.NCT06409195 A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin CancersNon-Melanoma Skin Cancersunknown50
2024-11 est.P2Sao Thai Duong Joint Stock CompanyNCT06657495 To Evaluate the Safety and Efficacy of TD0015 Pilulae in Patients with Knee OsteoarthritisKnee Osteoarthritisunknown90
2024-11-01P3Pfizer PFENCT04188509 Open-Label Extension of VoxelotorSickle Cell Diseaseterminated162
2024-11-01P3Shanghai Biomabs Pharmaceutical Co., Ltd.NCT04591275 Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® .Postmenopausal Osteoporosiscompleted278
2024-11-01 est.P2Celltex Therapeutics CorporationNCT05017298 Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem CellsCorona Virus Infection; Covid19unknown30
2024-11-01P2RemedyNCT05067244 A Phase 2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD)Post Traumatic Stress Disordercompleted10
2024-11-01 est.P2AGO Research GmbHNCT05126342 Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPiRecurrent Ovarian Cancer; Recurrent Fallopian Tube Cancer; Primary Peritoneal Cancerwithdrawn
2024-11-01P2BioVersys AGNCT05685615 PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRABVentilator Associated Pneumoniacompleted39
2024-11-01 est.P2Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT05938179 A Study of HS-10353 in Adult Participants With Major Depressive DisorderMajor Depressive Disorder (MDD)unknown144
2024-11-01P2Novartis Pharmaceuticals NVSNCT06142383 A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart FailureHeart Failureterminated136
2024-11-01P2InventisBio Co., LtdNCT06278350 Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque PsoriasisPlaque Psoriasiscompleted161
2024-11-01P3GlaxoSmithKlineNCT06374394 A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in ARespiratory Syncytial Virus Infectionscompleted841
2024-11-03P3Aldeyra Therapeutics, Inc. ALDXNCT06424444 A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye DiseaseDry Eye Diseasecompleted421
2024-11-04P1/P2Bristol-Myers Squibb BMYNCT03377361 An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer ofColorectal Cancer; Colorectal Tumors; Colorectal Carcinoma; Colorectal Neoplasmcompleted325
2024-11-04P1/P2Epizyme, Inc.NCT04179864 A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate CancerMetastatic Prostate Cancer; Metastatic Castration-resistant Prostate Cancerterminated102
2024-11-04P2AstraZeneca AZNNCT05246514 A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLCHER2-mutant Non-Small Cell Lung Canceractive not recruiting72
2024-11-04P2Novartis Pharmaceuticals NVSNCT05445843 Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell LLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expresactive not recruiting95
2024-11-04P3LG ChemNCT05586958 Tigulixostat, Phase 3 Study, Placebo Controlled in Gout PatientsGout; Hyperuricemia; Gout Flare; Tophicompleted354
2024-11-04P3Viridian Therapeutics, Inc. VRDNNCT06021054 An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)Thyroid Eye Diseasecompleted188
2024-11-04P2River 2 Renal Corp.NCT06264310 To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)Heart Failure; Worsening Heart Failure (WHF)completed33
2024-11-06P2Novartis Pharmaceuticals NVSNCT03474965 Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease PatientsSickle Cell Disease (SCD)completed117
2024-11-06P2/P3Janssen Pharmaceutical K.K.NCT04630145 A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)completed129
2024-11-06P3AbbVie ABBVNCT05028569 Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic MigraineEpisodic Migraineterminated775
2024-11-06P2Hoffmann-La RocheNCT05151731 A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular EdemaDiabetic Macular Edemacompleted394
2024-11-06P2Takeda TAKNCT05353985 A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free DietCeliac Diseasecompleted153
2024-11-06P3Sanofi SNYNCT05405166 SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMMPlasma Cell Myeloma Recurrentactive not recruiting531
2024-11-06P3LG ChemNCT05431933 Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting SchePoliomyelitis; Vaccine Reactioncompleted2001
2024-11-06P3Merck Sharp & Dohme LLC MRKNCT06212752 A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With MetastatiMetastatic Non-small Cell Lung Canceractive not recruiting39
2024-11-06P2Clexio Biosciences Ltd.NCT06262607 A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia ParestheticaChronic Pruritus in Adult Subjects With Notalgia Paresthetica (NP)completed59
2024-11-06P3Haisco Pharmaceutical Group Co., Ltd.NCT06391931 A Multicenter, Open, Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Cipepofol Injection for General Anesthesia in Pediatric PatientAnesthesiacompleted190
2024-11-07P1/P2Bristol-Myers Squibb BMYNCT03369223 A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid TumorsAdvanced Cancercompleted356
2024-11-07P1/P2Lexeo Therapeutics LXEONCT03634007 Gene Therapy for APOE4 Homozygote of Alzheimer's DiseaseAlzheimer Disease; Early Onset Alzheimer Diseasecompleted15
2024-11-07P3Novartis Pharmaceuticals NVSNCT03769168 An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)Juvenile Psoriatic Arthritis; Enthesitis Related Arthritiscompleted55
2024-11-07P2MapregNCT03870776 RESIST : Administration of MAP4343 in Antidepressant Non-Responders Patients Experiencing a Major Depressive EpisodeDepressioncompleted126
2024-11-07P2Fulcrum Therapeutics FULCNCT04264442 Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)Facioscapulohumeral Muscular Dystrophy (FSHD)terminated76
2024-11-07P2Novartis Pharmaceuticals NVSNCT04452877 A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLCCarcinoma, Non-Small-Cell Lungcompleted40
2024-11-07P3Bristol-Myers Squibb BMYNCT04908189 A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to BioPsoriatic Arthritisactive not recruiting729
2024-11-07P1/P2Armata Pharmaceuticals, Inc. ARMPNCT05184764 Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus BacteremiaBacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Ducompleted56
2024-11-07P3BayerNCT05850520 A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to SwelliMacular Edema Secondary to Retinal Vein Occlusioncompleted892
2024-11-07P2Affimed GmbHNCT05883449 Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCLRelapsed or Refractory Hodgkin Lymphoma; Peripheral T Cell Lymphomaterminated25
2024-11-07P3Outlook Therapeutics, Inc. OTLKNCT06190093 A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)Neovascular Age-related Macular Degeneration; Age-Related Macular Degeneration; Wet Macular Degeneracompleted400
2024-11-08P1/P2Sanofi SNYNCT03284957 Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor PosiBreast Cancerterminated136
2024-11-08P1/P2Eli Lilly and Company LLYNCT03899792 A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) TumorsMedullary Thyroid Cancer; Infantile Myofibromatosis; Infantile Fibrosarcoma; Papillary Thyroid Canceactive not recruiting36
2024-11-08P3ModernaTX, Inc.NCT05330975 A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of AgeRespiratory Syncytial Viruscompleted3317
2024-11-08P3Janssen Research & Development, LLCNCT05550532 A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to CurreDepressive Disorder, Major; Anhedoniacompleted444
2024-11-08P2Kezar Life Sciences, Inc.NCT05781750 A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)Lupus Nephritisterminated84
2024-11-08P2MC2 TherapeuticsNCT06132919 Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS)Vulvar Lichen Sclerosuscompleted33
2024-11-08P3Colgate Palmolive CLNCT06486974 Efficacy of Manual Toothbrushes in Removing Tooth StainsTooth Discolorationcompleted80
2024-11-08P2Asceneuron S.A.NCT06677203 Study of ASN51 in Adults With Early Alzheimer's DiseaseAlzheimer Diseaseterminated123
2024-11-10 est.P2Gannex Pharma Co., Ltd.NCT05118360 Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASHNonalcoholic Steatohepatitis (NASH)withdrawn
2024-11-10P1/P223andMe, Inc.NCT06290388 Study of 23ME-01473 in Patients With Advanced Solid MalignanciesSolid Tumorterminated5
2024-11-11P2Taiho Oncology, Inc.NCT04189445 Futibatinib in Patients With Specific FGFR AberrationsAdvanced or Metastatic Solid Tumor; Advanced or Metastatic Gastric or Gastroesophageal Cancer; Myeloterminated115
2024-11-11P2Sun Pharmaceutical Industries LimitedNCT04684485 To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic DermatitisDermatitis, Atopiccompleted250
2024-11-11 est.P2Aphaia Pharma US LLCNCT05385978 A Study of Distal Jejunal-release Dextrose in Obese ParticipantsObeseunknown150
2024-11-11P3Sanofi SNYNCT05526521 A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous UrticariaChronic Spontaneous Urticariacompleted15
2024-11-11P1/P2Lubris Bio Pty LtdNCT06520202 RHPRG4 FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASESjogren's Syndrome With Dry Eyeterminated8
2024-11-11P3HTA Co., Ltd.NCT07119242 Evaluate the Diagnostic Efficacy, Pharmacokinetics and Safety of 68Ga-DOTATATE Injection PET/CT in NETsNETsactive not recruiting95
2024-11-11P2Daewon Pharmaceutical Co., Ltd.NCT07319520 Clinical Trial to Evaluate the Efficacy and Safety of DW4902Myoma of Uteruscompleted71
2024-11-12P1/P2Bristol-Myers Squibb BMYNCT01658878 An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With AdvanHepatocellular Carcinomacompleted657
2024-11-12P3Sarepta Therapeutics, Inc. SRPTNCT02500381 Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)Duchenne Muscular Dystrophycompleted228
2024-11-12P3Pfizer PFENCT03573882 Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031Sickle Cell Diseaseterminated179
2024-11-12P3PharmaEssentiaNCT04285086 Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or IntoleranceEssential Thrombocythemiaactive not recruiting174
2024-11-12P2Gilead Sciences GILDNCT04971785 Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)Nonalcoholic Steatohepatitiscompleted457
2024-11-12P3Novartis Pharmaceuticals NVSNCT05089656 Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA)Type 2 Spinal Muscular Atrophycompleted126
2024-11-12P1/P2Arrowhead Pharmaceuticals ARWRNCT05292950 Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung DiseaseAsthma; Chronic Obstructive Pulmonary Diseaseterminated78
2024-11-12P2Teva Branded Pharmaceutical Products R&D, Inc.NCT05499130 A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's DiseaseCrohn Disease; Colitis, Ulcerativecompleted290
2024-11-12P2Smilebiotek Zhuhai LimitedNCT05536752 QA102 Phase II Study in Subjects With Dry AMDDry Age-related Macular Degenerationcompleted150
2024-11-12P1/P2Shanghai Juncell TherapeuticsNCT06120712 A Study of GC101 TIL in Advanced Melanoma (BZ)Tumor Infiltrating Lymphocytes; Safety; Melanoma; Efficacy; Adverse Drug Eventcompleted18
2024-11-13P3Syros PharmaceuticalsNCT04797780 Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic SyndromeMyelodysplastic Syndromesterminated246
2024-11-13P1/P2Repare TherapeuticsNCT04972110 Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid TumorsAdvanced Solid Tumor, Adultterminated156
2024-11-13P3Novo Nordisk A/S NVONCT05306418 A Research Study Looking at Mim8 in Children With Haemophilia A With or Without InhibitorsHaemophilia A With or Without Inhibitorscompleted70
2024-11-13P3Eli Lilly and Company LLYNCT05822830 A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related ComorbiditiesObesity; Overweightcompleted751
2024-11-13P2GH Research Ireland LimitedNCT05839509 Phase 2 Clinical Trial of GH001 in Bipolar II DisorderBipolar II Disorderterminated6
2024-11-13P2Sanofi SNYNCT06073119 A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque PsoriasisPsoriasiscompleted221
2024-11-13P2AkesoNCT06092762 A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic DermatitisAtopic Dermatitiscompleted180
2024-11-14P2InFlectis BioScienceNCT05508074 Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol)Amyotrophic Lateral Sclerosis; ALScompleted51
2024-11-14P2ApcinteX LtdNCT05789524 The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia BHemophilia a; Hemophilia Bterminated60
2024-11-14P2ApcinteX LtdNCT05789537 A Study of SerpinPC in Participants with Hemophilia B (HemB) with InhibitorsHemophilia B with Inhibitor; Hemophilia Bterminated3
2024-11-14P3Alcon Research ALCNCT06444529 A Double-Masked Comparison of FID 123320 Ophthalmic Solution to Vehicle for the Reduction of Ocular RednessOcular Rednesscompleted159
2024-11-14P3Sedana MedicalNCT06809218 A Pooled Analysis of Long-Term Outcomes After Inhaled Isoflurane Via the Sedaconda ACD-S Compared to Intravenous PropofolPost-Intensive Care Syndrome; Sedationactive not recruiting312
2024-11-15P2Istari Oncology, Inc.NCT04577807 LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory MelanomaMelanomacompleted27
2024-11-15P2Verastem, Inc. VSTMNCT04625270 A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS MutationLow Grade Ovarian Serous Adenocarcinoma; Ovarian Canceractive not recruiting225
2024-11-15P3Axsome Therapeutics, Inc. AXSMNCT05113745 A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)Narcolepsy; Cataplexy; Excessive Daytime Sleepinesscompleted68
2024-11-15P2Jiangsu HengRui Medicine Co., Ltd.NCT05367687 A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High RisAdjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Cucompleted251
2024-11-15P2ModernaTX, Inc.NCT05584202 Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in InfantsSARS-CoV-2terminated68
2024-11-15P3Alexion Pharmaceuticals, Inc.NCT05778071 Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic HypoparathyroidismChronic Hypoparathyroidism; Endocrine System Diseases; Parathyroid Diseasesactive not recruiting165
2024-11-15P2Artios Pharma LtdNCT05798611 Study of ART0380 in Patients With Biologically Selected Solid TumorsAdvanced Solid Tumor; Recurrent Endometrial Cancer; Metastatic Cancerterminated36
2024-11-15P2Reata, a wholly owned subsidiary of BiogenNCT05895552 A Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic PainDiabetic Peripheral Neuropathic Painterminated209
2024-11-15 est.P2NeuTherapeuticsNCT06186531 PhytoSERM for Menopausal Hot Flashes and Sustained Brain HealthMenopause; Hot Flashesunknown132
2024-11-15P3Janssen Research & Development, LLCNCT06220604 A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)Plaque Psoriasisactive not recruiting731
2024-11-15P2Shandong Suncadia Medicine Co., Ltd.NCT06393348 Efficacy and Safety of HRS-7535 Tablets in T2DM Subjects Poorly Controlled With Metformin and SGLT2i.Type 2 Diabetescompleted155
2024-11-15P3Huabo Biopharm Co., Ltd.NCT06477237 Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque PsoriasisPsoriasiscompleted408
2024-11-15 est.P1/P2Frontera TherapeuticsNCT06492876 Gene Therapy for DMEDiabetic Macular Edemarecruiting78
2024-11-17 est.P3Beijing Health Guard Biotechnology, IncNCT06207175 A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) VaccineHuman Papillomavirus Infectionunknown1260
2024-11-18P3Grünenthal GmbHNCT05248386 Efficacy and Safety of RTX-GRT7039 in Adult Subjects With Knee OsteoarthritisOsteoarthritiscompleted469
2024-11-18P2COMPASS Pathways CMPSNCT05481736 Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept StudyAnorexia Nervosacompleted32
2024-11-18P2Chipscreen Biosciences, Ltd.NCT05519865 A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLCNon Small Cell Lung Cancercompleted118
2024-11-18P3AstraZeneca AZNNCT05555290 PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway ObstructionAsthmacompleted190
2024-11-18P1/P2Biomea Fusion Inc. BMEANCT05731544 Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)Type 2 Diabetes Mellituscompleted443
2024-11-18P2Shandong Suncadia Medicine Co., Ltd.NCT06516068 A Trial of HRS-1893 in Patients With Obstructive Hypertrophic CardiomyopathyObstructive Hypertrophic Cardiomyopathyactive not recruiting42
2024-11-19P1/P2TCR2 TherapeuticsNCT03907852 Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing CancerMesothelioma; Mesothelioma, Malignant; Mesothelioma; Pleura; Mesotheliomas Pleural; Mesothelioma Peractive not recruiting57
2024-11-19P3Fulcrum Therapeutics FULCNCT05397470 Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)Facioscapulohumeral Muscular Dystrophy (FSHD)terminated260
2024-11-19P1/P2Ichnos Sciences SANCT05427812 Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Multiple Myelomaterminated29
2024-11-19P3AstraZeneca AZNNCT05755906 A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in PartAsthmacompleted374
2024-11-19P2Percheron TherapeuticsNCT05938023 A Study of ATL1102 or Placebo in Participants With Non-ambulatory Duchenne Muscular DystrophyDuchenne Muscular Dystrophyterminated48
2024-11-19P3Invivyd, Inc. IVVDNCT06039449 A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of ExpoCOVID-19; SARS-CoV-2completed790
2024-11-19P2Regeneron Pharmaceuticals REGNNCT06454630 A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult ParticipantsVenous Thromboembolismcompleted179
2024-11-19P3Prime Gene Therapeutics Co., Ltd.NCT06587685 A Study to Assess the Efficacy and Safety of PG-011 Gel in Adolescents and Adults With Atopic DermatitisAtopic Dermatitisrecruiting472
2024-11-20P2Respira Therapeutics, Inc.NCT04266197 Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B StudyPulmonary Arterial Hypertensioncompleted42
2024-11-20P2Sun Pharmaceutical Industries LimitedNCT04566666 To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque PsoriasisModerate to Severe Plaque Psoriasiscompleted263
2024-11-20P1/P2Suzhou Junde Biotechnology Co., LtdNCT04843098 Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaHead and Neck Squamous Cell Carcinomaactive not recruiting108
2024-11-20P3Merck Sharp & Dohme LLC MRKNCT05093933 A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)Chronic Heart Failure With Reduced Ejection Fractioncompleted6106
2024-11-20P2EMD Serono Research & Development Institute, Inc.NCT05162586 The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)Systemic Lupus Erythematosuscompleted456
2024-11-20P1/P2TaiMed Biologics Inc.NCT05275998 TMB-365 and TMB-380 in Suppressed HIV-1 Infected IndividualsHIV-1-infectioncompleted51
2024-11-20 est.P1/P2ViGenCell Inc.NCT05276076 A Prospective, Open Label, Dose-escalation, SAD/MAD, Multicenter, 24weeks, Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamics Graft Versus Host Diseaseunknown12
2024-11-20P3Hoffmann-La RocheNCT05415215 A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in ParticEarly Breast Cancer; Locally Advanced Breast Cancer; Inflammatory Breast Cancercompleted346
2024-11-20P2AstraZeneca AZNNCT05498155 Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast CancerBreast Cancercompleted50
2024-11-20P2ImmuneSensor Therapeutics Inc.NCT05846659 Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor MalignanciesOligoprogressiveterminated16
2024-11-20P3Yangtze River Pharmaceutical Group Co., Ltd.NCT06904248 Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-severe Pain Following Abdominal SurgeryParticipants With Acute Moderate to Severe Pain Following Abdominal Surgerycompleted224
2024-11-21P3Novo Nordisk A/S NVONCT04865770 A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL TrDiabetes Mellitus, Type 2; Chronic Kidney Diseasecompleted106
2024-11-21P1/P2Omega Therapeutics OHINCT05497453 A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC OncogeneHepatocellular Carcinoma; Solid Tumor; Hepatocellular Carcinoma Non-resectable; Hepatocellular Carciterminated24
2024-11-21P3Axsome Therapeutics, Inc. AXSMNCT05557409 A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease AgitationAgitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitationcompleted408
2024-11-21P2Sanofi SNYNCT05630547 A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple SclerosisMultiple Sclerosisterminated174
2024-11-21P2Beijing Mabworks Biotech Co., Ltd.NCT05796206 A Phase 2 Clinical Study of MIL62 in Systemic Lupus ErythematosusSystemic Lupus Erythematosuscompleted123
2024-11-21P1/P2Servier Bio-Innovation LLCNCT05921760 Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant CholangiocarcinomaIDH1-mutant Cholangiocarcinomaterminated7
2024-11-21P2Laboratoires TheaNCT06394973 Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular HypertensionGlaucoma; Ocular Hypertensioncompleted161
2024-11-22P1/P2NeoImmuneTechNCT04332653 NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid TumorsAny Advanced Solid Tumors; Triple Negative Breast Cancer; Non Small Cell Lung Cancer; Small Cell Luncompleted215
2024-11-22P3Otsuka Beijing Research InstituteNCT05583474 OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese SubjectsOpen Angle Glaucoma or Ocular Hypertensioncompleted204
2024-11-22P3Meiji Seika Pharma Co., Ltd.NCT05887908 Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or AcutComplicated Urinary Tract Infection; Acute Pyelonephritis; cUTI; APcompleted614
2024-11-22P2Chengdu Suncadia Medicine Co., Ltd.NCT05905458 A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or NucleoChronic Hepatitis Bcompleted54
2024-11-22P3Nanjing Chia-tai Tianqing PharmaceuticalNCT06076486 A Clinical Trial to Evaluate Efficacy and Safety of Elagolix Tablets in Women With Moderate or Severe Endometriosis-associated PainEndometriosiscompleted202
2024-11-22P2Zydus Lifesciences LimitedNCT06398808 A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Ulcerative Colitiscompleted24
2024-11-22P2/P3Biomed Industries, Inc.NCT06849973 To Study the Efficacy & Safety of Oral NA-921 (Bionetide) in Girls and Women with Rett SyndromeRett Syndromecompleted187
2024-11-23P3Jiangsu HengRui Medicine Co., Ltd.NCT05699408 To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic DruType 2 Diabetescompleted513
2024-11-23 est.P3Changchun GeneScience Pharmaceutical Co., Ltd.NCT06561594 To Evaluate Recombinant Human Follicle Stimulating Hormone-CTP Fusion Protein Injection or Placebo Combined With Chorionic Gonadotropin for InjectionIdiopathic Hypogonadotropic Hypogonadismnot yet recruiting60
2024-11-24 est.P3Qilu Pharmaceutical Co., Ltd.NCT05950516 Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 DiabetesType 2 Diabetesunknown478
2024-11-25P2Bausch Health Americas, Inc.NCT03596905 Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bowel Syndrome With Constipation (IBS-C)Irritable Bowel Syndrome With Constipationcompleted218
2024-11-25P3WockhardtNCT04979806 Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)Complicated Urinary Tract Infection; Acute Pyelonephritiscompleted530
2024-11-25P2Cognition Therapeutics CGTXNCT05225415 Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy BodiesDementia With Lewy Bodiescompleted130
2024-11-25P1/P2Avidity Biosciences, Inc.NCT05670730 Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 SkippingDuchenne Muscular Dystrophy; Exon 44completed70
2024-11-26P2Sanofi SNYNCT03996291 Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple SclerosisRelapsing Multiple Sclerosiscompleted125
2024-11-26P2Clarity Pharmaceuticals LtdNCT04438304 A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)Neuroendocrine Tumorscompleted45
2024-11-26P3Alexion Pharmaceuticals, Inc.NCT04557735 Study of Ravulizumab in Pediatric Participants With HSCT-TMAThrombotic Microangiopathycompleted41
2024-11-26P1/P2Siolta Therapeutics, Inc.NCT05003804 Allergic Disease Onset Prevention StudyAtopic Dermatitis; Type 1 Hypersensitivitycompleted283
2024-11-26P3RemeGen Co., Ltd.NCT05737160 Study of Telitacicept in Generalized Myasthenia GravisMyasthenia Gravis, Generalizedcompleted114
2024-11-26P3Visirna Therapeutics HK LimitedNCT05902598 A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia SyndromeFamilial Chylomicronemia Syndromecompleted37
2024-11-26P2Genome & CompanyNCT05998447 GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract CancerBiliary Tract Cancerterminated10
2024-11-26P3BioNTech SE BNTXNCT06178991 A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.Influenza; COVID-19completed8795
2024-11-26P2Shanghai Hutchison Pharmaceuticals LimitedNCT06202378 Safety and Efficacy of SHPL-49 Injection in Participants With Acute Ischemic StrokeAcute Ischemic Strokecompleted270
2024-11-26P3Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USANCT06460493 Effect of Ensifentrine Treatment on CAT ScoreCOPDcompleted20
2024-11-27P3ITM Solucin GmbHNCT03049189 Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET PatientsNeuroendocrine Tumorsactive not recruiting324
2024-11-27P2Tasly Pharmaceutical Group Co., LtdNCT04983043 Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart FailureChronic Heart Failure With Reduced Ejection Fractioncompleted228
2024-11-27P1/P2Lassen Therapeutics 1 PTY LTDNCT05331300 A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or ThPulmonary Fibrosis; Thyroid Eye Diseasecompleted75
2024-11-27P3Axsome Therapeutics, Inc. AXSMNCT05550207 Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)Migrainecompleted100
2024-11-27P2Novo Nordisk A/S NVONCT06064006 A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the SkinObesity; Overweightcompleted125
2024-11-28P3Eli Lilly and Company LLYNCT04232553 A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's DiseaseCrohn's Diseaseactive not recruiting996
2024-11-28P3Janssen Research & Development, LLCNCT04673357 A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's DiseaseCrohn Diseasecompleted101
2024-11-28P2Alterity Therapeutics ATHENCT05109091 Study of ATH434 in Participants with Multiple System AtrophyMultiple System Atrophycompleted77
2024-11-28P3Amgen AMGNNCT05398445 A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)Atopic Dermatitiscompleted769
2024-11-28P2Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)NCT05611671 A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UCInflammatory Bowel Diseases; Colitis, Ulcerativecompleted280
2024-11-28P2Ophirex, Inc.NCT05717062 Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)Snakebite; Envenoming, Snakecompleted140
2024-11-28P3GuerbetNCT06057168 Performance of Elucirem in DSC-MRI Perfusion of Brain GliomasBrain Tumor, Primary; Brain Tumor, Recurrentcompleted138
2024-11-28P3Polisorb Joint Stock CompanyNCT07929181 Efficacy and Safety of Polisorb® MP in the Complex Therapy of Patients With Atopic DermatitisAtopic Dermatitiscompleted161
2024-11-29P3NovoCure GmbH NVCRNCT02831959 Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung CancerBrain Metastases From Non-small Cell Lung Cancer (NSCLC)completed298
2024-11-29P1/P2AstraZeneca AZNNCT03742102 A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast CancerTriple Negative Breast Neoplasmsactive not recruiting243
2024-11-29P3Amicus TherapeuticsNCT04049760 Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry DiseaseFabry Diseasecompleted16
2024-11-29P3Hoffmann-La RocheNCT04182204 A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, GemcitabineDiffuse Large B-Cell Lymphomacompleted270
2024-11-29P1/P2Geneos TherapeuticsNCT04251117 GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCCHCCactive not recruiting36
2024-11-29P3Teva Branded Pharmaceutical Products R&D, Inc.NCT04464707 A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of AgeMigrainecompleted292
2024-11-29 est.P3Merck Sharp & Dohme LLC MRKNCT04859582 Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-85Stomach Neoplasmswithdrawn
2024-11-29P3Novartis Pharmaceuticals NVSNCT05386680 Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who DiscoSpinal Muscular Atrophycompleted27
2024-11-29P1/P2Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SANCT05574010 A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)Celiac Diseaseterminated128
2024-11-29 est.P2AnaptysBio, Inc. ANABNCT06041269 A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)Rheumatoid Arthritisactive not recruiting420
2024-11-29P2Shanxi Kangbao Biological Product Co., Ltd.NCT06061536 Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients.HIVcompleted64
2024-11-29P3Olive HealthcareNCT06597175 Evaluating Investigational Medical Device for Breast Tumor Diagnosis Using Diffusion Optical SpectroscopyBreast Cancer; Breast Tumor; Mammary Carcinoma, Humancompleted300
2024-11-30P1/P2Cyteir Therapeutics, Inc.NCT03997968 A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid TumorsMalignancy; Non-hodgkin Lymphoma; Multiple Myeloma; Breast Cancer; Ovarian Cancer; Soft Tissue Sarcocompleted169
2024-11-30P1/P2Ascentage Pharma Group Inc. AAPGNCT04284488 Dose-escalation Study of APG-1387 and Toripalimab in Solid TumorsAdvanced Solid Tumorterminated40
2024-11-30P1/P2Otsuka Pharmaceutical Co., Ltd.NCT04362007 A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell LymphomaRelapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cellterminated8
2024-11-30 est.P1/P2NexImmune Inc.NCT04505813 Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple MyelomaRelapsed Refractory Multiple Myelomasuspended9
2024-11-30 est.P1/P2LintonPharm Co.,Ltd.NCT04799847 Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG VaccineBladder Cancerunknown161
2024-11-30P3Hutchison Medipharma LimitedNCT04923945 Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) PatientsNon-small Cell Lung Cancer Metastaticcompleted203
2024-11-30 est.P3Jiangsu HengRui Medicine Co., Ltd.NCT04961710 Extension Study of Hetrombopag in Severe Aplastic AnemiaTreatment-naive Severe Aplastic Anemiaunknown157
2024-11-30P3IpsenNCT05027802 A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia OssificFibrodysplasia Ossificans Progressiva (FOP)completed61
2024-11-30 est.P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT05349409 A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing CancersAdvanced Solid Tumorsunknown212
2024-11-30 est.P2/P3ShaperonNCT05352347 Phase 2b/3 Trial of NuSepin® in COVID-19 Pneumonia PatientsCOVID-19 Pneumoniaunknown1134
2024-11-30 est.P1/P2CANbridge (Suzhou) Bio-pharma Co., Ltd.NCT05447494 Phase 1/2 Study of CAN103 in Subjects With Gaucher DiseaseGaucher Disease, Type 1; Gaucher Disease, Type 3unknown40
2024-11-30 est.P2WestVac Biopharma Co., Ltd.NCT05465902 Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a BoosterCOVID-19; SARS-CoV-2 Infectionwithdrawn
2024-11-30P2Hutchmed HCMNCT05467943 Tazemetostat for the Treatment of Relapsed/Refractory Follicular LymphomaRelapsed/Refractory Follicular Lymphoma With EZH2completed42
2024-11-30P2Stella Pharma CorporationNCT05601232 A Phase II Study by Using CICS-1 and SPM-011 Commissioned by CICS and STELLA PHARMAUnresectable Angiosarcomaactive not recruiting10
2024-11-30P2Biocity Biopharmaceutics Co., Ltd.NCT05687890 A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney DiseaseDiabetic Kidney Disease; IgA Nephropathyunknown255
2024-11-30 est.P1/P2Innovent Biologics (Suzhou) Co. Ltd.NCT05923008 A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid TumorsSolid Tumorunknown182
2024-11-30 est.P2AkesoNCT05960955 Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction AdenocarcinomaResectable Gastric or Gastroesophageal Junction Adenocarcinomarecruiting90
2024-11-30P1/P2Innovent Biologics (Suzhou) Co. Ltd.NCT05991349 A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid TumorsSolid Tumorcompleted36
2024-11-30 est.P3Huons BiopharmaNCT06205797 To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)Glabellar Linesunknown312
2024-11-30 est.P2Grand Medical Pty Ltd.NCT06548854 A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Dose Exploration Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic CharacSepsisunknown180

← 2024-10 | 2024-12 →

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.